• Bifendate Attenuates Hepatic Steatosis in Mice

  2026-09-10

  The 2006 European Journal of Pharmacology study showed that Bifendate, or DDB, consistently reduced hepatic cholesterol and triglyceride accumulation across several mouse models of diet- and cholesterol-induced hypercholesterolemia. Its key contribution was to distinguish liver lipid reduction from systemic lipid lowering, providing a useful framework for studying hepatoprotection and hepatic lipid metabolism rather than treating DDB as a conventional serum lipid-lowering drug.

• FH1 Small Molecule for iHep Maturation

  2026-09-10

  FH1 (Catalog No. B3700) supports a more functional hepatocyte-like cell workflow by pairing morphology with albumin, CYP3A4, and AFP readouts. This guide shows how to build a controlled iPS differentiation experiment, troubleshoot inconsistent maturation, and evaluate how improved cell state may support regulated gene-expression studies.

• Arrb2–6-ketoLCA Signaling in Hepatic IRI

  2026-09-09

  The reference study identifies hepatocyte β-arrestin 2 (Arrb2) as a protective regulator of hepatic ischemia–reperfusion injury, linking parenchymal signaling to increased 6-ketoLCA and M2 macrophage polarization. Its combination of clinical association analysis, hepatocyte-focused mouse genetics, hypoxia–reoxygenation experiments, and metabolomics offers a useful framework for studying hepatocyte–macrophage communication in transplantation-related inflammation.

• Ferrostatin-1 in NRF2-Linked Ferroptosis Assays

  2026-09-09

  Ferrostatin-1 (Fer-1) is a selective tool for separating ferroptotic lipid damage from broader oxidative and inflammatory effects. This article explains how to use Fer-1 as a mechanistic rescue control in NRF2-focused alcoholic liver disease assays and related disease models.

• Saracatinib (AZD0530) Assay Workflows

  2026-09-08

  Build reproducible Src/Abl inhibition studies with Saracatinib (AZD0530), from dose-response and migration assays to pathway validation. The workflow also explains how findings on Reelin–SFK signaling can inform exploratory neurobiology without overstating cross-domain evidence.

• MK-5108 (VX-689): From Target to Tumor Model

  2026-09-08

  Explore how MK-5108 (VX-689), a highly selective Aurora A inhibitor, can connect target validation with cancer cell line proliferation assays and xenograft studies. This article emphasizes assay design, evidence interpretation, and translational limitations rather than repeating standard product or disease summaries.

• Caspase-3 Fluorometric Assay Kit Workflow

  2026-09-07

  Turn apoptosis experiments into quantitative caspase activity measurements with a fast DEVD-AFC fluorescence workflow. This guide shows how to connect treatment design, autophagy–apoptosis biology, controls, and troubleshooting for more interpretable results.

• ABT-888 (Veliparib) in Translational DDR Research

  2026-09-07

  ABT-888 (Veliparib) offers translational researchers a selective PARP1/2 perturbation tool for testing DNA repair inhibition, chemotherapy and radiation sensitization, and genotype-dependent response. This thought-leadership analysis connects preclinical colorectal cancer evidence with a recent acute leukemia study showing why DNA damage-response combinations must be evaluated in the correct biological context.

• c-Myc Tag Peptide: From Assay Control to Translation

  2026-09-05

  A mechanistic and strategic guide to using the c-Myc tag Peptide for epitope-specific assay control, fusion-protein displacement, and more disciplined translational studies of transcription factor regulation.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-09-04

  The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 and LLY507 in animal and tubular epithelial cell models, the researchers connected SMYD2 inhibition with improved renal injury, reduced fibrogenic and inflammatory signaling, and modulation of Smad3, STAT3, and Smad7.

• HDAC6-Driven α-Tubulin Lactylation and Dynamics

  2026-09-04

  The reference study identifies α-tubulin lactylation at Lys40 as a metabolism-sensitive modification that promotes microtubule dynamics in neuronal cells. It further establishes HDAC6 as a catalytic writer of this modification, linking intracellular lactate to cytoskeletal remodeling, neurite outgrowth, and branching.

• β-Amanitin: From Transcription Tool to Toxin Sensor

  2026-09-03

  β-Amanitin is both a selective RNA polymerase II inhibitor and a useful reference analyte for understanding amatoxin detection. This article connects transcription biology, assay design, and the latest dual-target mushroom-toxin sensing evidence.

• H 89 2HCl for cAMP/PKA Signaling Assays

  2026-09-03

  Use H 89 2HCl to separate downstream PKA activity from upstream cAMP production in phosphorylation, neurite-growth, and neuroinflammation assays. This guide translates recent trigeminal pain findings into practical controls, dosing strategies, and troubleshooting steps while emphasizing H 89’s concentration-dependent kinase selectivity.

• Neurotensin: NTR1 Signaling and GPCR Trafficking

  2026-09-02

  Neurotensin is a 13-amino acid neuropeptide and a useful Neurotensin receptor 1 activator for studying G protein-coupled receptor signaling. The B5226 reagent combines vendor-reported high purity with defined molecular, solubility, and storage specifications for GPCR trafficking mechanism study and miRNA regulation in gastrointestinal cells.

• Reserpine (N1867): Practical Research Workflow

  2026-09-02

  Reserpine (SKU N1867) provides a characterized research reagent for controlled neurotransmitter depletion, antihypertensive mechanism, and neuropharmacology workflows where solvent compatibility and solution freshness affect reproducibility. It is intended for research use only and should not be used for diagnostic, therapeutic, medical, or veterinary applications.

8487 records 1/566 page Next 12345 下5页 Last page